Liquid biopsy to personalize treatment for metastatic prostate cancer

被引：0
作者：
Lopez-Valcarcel, Marta [1 ,10 ]
Lopez-Campos, Fernando [2 ]
Zafra, Juan [3 ]
Cienfuegos, Irene [4 ]
Ferri, Maria [5 ]
Barrado, Marta [6 ]
Hernando, Susana [7 ]
Counago, Felipe [8 ,9 ]
机构：
[1] Puerta de Hierro Univ Hosp, Dept Radiat Oncol, Madrid, Spain
[2] Ramon y Cajal Univ Hosp, Dept Radiat Oncol, Madrid, Spain
[3] Virgen de la Victoria Univ Hosp, Dept Radiat Oncol, Malaga, Spain
[4] Virgen del Puerto Hosp, Dept Urol, Caceres, Extremadura, Spain
[5] Marques de Valdecilla Univ Hosp, Dept Radiat Oncol, Santander, Cantabria, Spain
[6] Univ Navarra, Dept Radiat Oncol, Pamplona, Navarra, Spain
[7] Fdn Alcorcon Univ Hosp, Dept Clin Oncol, Alcorcon, Madrid, Spain
[8] GenesisCare, San Francisco de Asis Hosp, Natl Chair Res & Clin Trials, Dept Radiat Oncol, Madrid, Spain
[9] GenesisCare, La Milagrosa Hosp, Natl Chair Res & Clin Trials, Dept Radiat Oncol, Madrid, Spain
[10] Puerta de Hierro Majadahonda Univ Hosp, Dept Radiat Oncol, C Joaquin Rodrigo 1, Majadahonda 28222, Madrid, Spain
来源：
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | 2024年 / 16卷 / 05期
关键词：
Liquid biopsy; prostate cancer; circulating tumor DNA; circulating tumor cells; extracellular vesicles; secretome; CIRCULATING TUMOR-CELLS; FREE DNA; PROGNOSTIC MARKERS; EXTRACELLULAR VESICLES; POOR-PROGNOSIS; BIOMARKER; PLASMA; ABIRATERONE; RESISTANCE; SURVIVAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Liquid biopsy is an innovative approach that provides a more complete understanding of treatment response and prognosis in monitoring metastatic prostate cancer. It complements invasive tissue biopsy and involves the assessment of various biomarkers in body fluids such as blood, semen, and urine. Liquid biopsy analyzes circulating tumor cells, extracellular vesicles, circulating tumor DNA, and the secretome. This is particularly important given the heterogeneity of prostate cancer and the need for better prognostic biomarkers. Liquid biopsy can personalize the treatment of homonosensitive and castration -resistant metastatic prostate cancer by acting as a predictive and prognostic tool. This review discusses various biomarkers, assay techniques, and potential applications in daily clinical practice, highlighting the exciting possibilities that this emerging field holds for improving patient outcomes.
引用
收藏
页码：1531 / 1549
页数：19
相关论文
共 147 条
  • [1] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
    Abida, Wassim
    Cheng, Michael L.
    Armenia, Joshua
    Middha, Sumit
    Autio, Karen A.
    Vargas, Hebert Alberto
    Rathkopf, Dana
    Morris, Michael J.
    Danila, Daniel C.
    Slovin, Susan F.
    Carbone, Emily
    Barnett, Ethan S.
    Hullings, Melanie
    Hechtman, Jaclyn F.
    Zehir, Ahmet
    Shia, Jinru
    Jonsson, Philip
    Stadler, Zsofia K.
    Srinivasan, Preethi
    Laudone, Vincent P.
    Reuter, Victor
    Wolchok, Jedd D.
    Socci, Nicholas D.
    Taylor, Barry S.
    Berger, Michael F.
    Kantoff, Philip W.
    Sawyers, Charles L.
    Schultz, Nikolaus
    Solit, David B.
    Gopalan, Anuradha
    Scher, Howard I.
    [J]. JAMA ONCOLOGY, 2019, 5 (04) : 471 - 478
  • [2] Agarwal N, 2022, J CLIN ONCOL, V40
  • [3] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    Allard, WJ
    Matera, J
    Miller, MC
    Repollet, M
    Connelly, MC
    Rao, C
    Tibbe, AGJ
    Uhr, JW
    Terstappen, LWMM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6897 - 6904
  • [4] Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
    Annala, M.
    Fu, S.
    Bacon, J. V. W.
    Sipola, J.
    Iqbal, N.
    Ferrario, C.
    Ong, M.
    Wadhwa, D.
    Hotte, S. J.
    Lo, G.
    Tran, B.
    Wood, L. A.
    Gingerich, J. R.
    North, S. A.
    Pezaro, C. J.
    Ruether, J. D.
    Sridhar, S. S.
    Kallio, H. M. L.
    Khalaf, D. J.
    Wong, A.
    Beja, K.
    Schonlau, E.
    Taavitsainen, S.
    Nykter, M.
    Vandekerkhove, G.
    Azad, A. A.
    Wyatt, A. W.
    Chi, K. N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (07) : 896 - 905
  • [5] Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
    Annala, Matti
    Vandekerkhove, Gillian
    Khalaf, Daniel
    Taavitsainen, Sinja
    Beja, Kevin
    Warner, Evan W.
    Sunderland, Katherine
    Kollmannsberger, Christian
    Eigl, Bernhard J.
    Finch, Daygen
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Azad, Arun A.
    Nykter, Matti
    Gleave, Martin E.
    Wyatt, Alexander W.
    Chi, Kim N.
    [J]. CANCER DISCOVERY, 2018, 8 (04) : 444 - 457
  • [6] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Mohammad, Tabrez A.
    Chen, Yidong
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 1028 - 1038
  • [7] Antonarakis ES, 2017, J Clin Oncol, P35
  • [8] Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
    Armstrong, Andrew J.
    Halabi, Susan
    Luo, Jun
    Nanus, David M.
    Giannakakou, Paraskevi
    Szmulewitz, Russell Z.
    Danila, Daniel C.
    Healy, Patrick
    Anand, Monika
    Rothwell, Colin J.
    Rasmussen, Julia
    Thornburg, Blair
    Berry, William R.
    Wilder, Rhonda S.
    Lu, Changxue
    Chen, Yan
    Silberstein, John L.
    Kemeny, Gabor
    Galletti, Giuseppe
    Somarelli, Jason A.
    Gupta, Santosh
    Gregory, Simon G.
    Scher, Howard I.
    Dittamore, Ryan
    Tagawa, Scott T.
    Antonarakis, Emmanuel S.
    George, Daniel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) : 1120 - +
  • [9] Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
    Barata, Pedro
    Agarwal, Neeraj
    Nussenzveig, Roberto
    Gerendash, Benjamin
    Jaeger, Ellen
    Hatton, Whitley
    Ledet, Elisa
    Lewis, Brian
    Layton, Jodi
    Babiker, Hani
    Bryce, Alan
    Garje, Rohan
    Stein, Cy
    Kiedrowski, Lesli
    Saylor, Philip
    Sartor, Oliver
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [10] Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer
    Barnett, Ethan S.
    Schultz, Nikolaus
    Stopsack, Konrad H.
    Lam, Ernest T.
    Arfe, Andrea
    Lee, Jerry
    Zhao, Jimmy L.
    Schonhoft, Joseph D.
    Carbone, Emily A.
    Keegan, Niamh M.
    Wibmer, Andreas
    Wang, Yipeng
    Solit, David B.
    Abida, Wassim
    Wenstrup, Richard
    Scher, Howard I.
    [J]. EUROPEAN UROLOGY, 2023, 83 (02) : 112 - 120
12345678910